Начало › Множествен миелом › Охайо › Cincinnati
Клинични проучвания за Множествен миелом в Cincinnati, OH
17 проучвания за Множествен миелом търсят участници в обекти в и около Cincinnati (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Набиране на участнициФаза 3
- Research Site, Cincinnati
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 3
- The Christ Hospital, Cincinnati
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Набиране на участнициФаза 3
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Набиране на участнициФаза 2
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · на 15 мили
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Набиране на участнициФаза 3
- University of Cincinnati Medical Center, Cincinnati
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 2
- Oncology Hematology Care, Cincinnati
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Набиране на участнициФаза 3
- TriHealth Cancer and Blood Institute, Cincinnati
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Набиране на участнициФаза 3
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- и още 4
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Набиране на участнициФаза 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- и още 1
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Набиране на участнициФаза 3
- Research Site, Cincinnati
- Research Site, Montgomery · на 11 мили
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Набиране на участнициФаза 1/2
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Набиране на участнициФаза 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- и още 2
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Набиране на участнициФаза 3
- University of Cincinnati, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Набиране на участнициФаза 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Набиране на участнициФаза 2
- Oncology Hematology Care, Cincinnati
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Oncology Hematology Care, Inc, Cincinnati
Проучвания за Множествен миелом в други градове
- New York City, NY60 проучвания
- Boston, MA42 проучвания
- Atlanta, GA41 проучвания
- Houston, TX38 проучвания
- Durham, NC37 проучвания
- Nashville, TN32 проучвания
- Denver, CO27 проучвания
- Rochester, MN24 проучвания
- St. Louis, MO24 проучвания
- Columbus, OH24 проучвания
- Baldwin Park, CA23 проучвания
- Chicago, IL22 проучвания
Други проучвания в Cincinnati
- Рак на белия дроб с недребноклетъчен тип35 проучвания
- Рак (всички видове)27 проучвания
- Рак на гърдата25 проучвания
- Сърдечна недостатъчност24 проучвания
- Колоректален рак21 проучвания
- Остра миелоидна левкемия20 проучвания
- Метастатичен рак20 проучвания
- Рак на яйчниците19 проучвания
- Рак на белия дроб19 проучвания
- Затлъстяване19 проучвания
- Рак на простатата18 проучвания
- Меланом17 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.